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Abstract
Background: Anatomically, cortical-basal ganglia-thalamo-cortical (CBGTC) circuits have an essential role in the expression of tics. At the biochemical level, the
proper conveyance of messages through these circuits requires several functionally integrated neurotransmitter systems. In this manuscript, evidence supporting
proposed pathophysiological abnormalities, both anatomical and chemical is reviewed. In addition, the results of standard and emerging tic-suppressing therapies
affecting nine separate neurotransmitter systems are discussed. The goal of this review is to integrate our current understanding of the pathophysiology of Tourette
syndrome (TS) with present and proposed pharmacotherapies for tic suppression.
Methods: For this manuscript, literature searches were conducted for both current basic science and clinical information in PubMed, Google-Scholar, and other
scholarly journals to September 2018.
Results: The precise primary site of abnormality for tics remains undetermined. Although many pathophysiologic hypotheses favor a specific abnormality of the
cortex, striatum, or globus pallidus, others recognize essential influences from regions such as the thalamus, cerebellum, brainstem, and ventral striatum. Some
prefer an alteration within direct and indirect pathways, whereas others believe this fails to recognize the multiple interactions within and between CBGTC circuits.
Although research and clinical evidence supports involvement of the dopaminergic system, additional data emphasizes the potential roles for several other
neurotransmitter systems.
Discussion: A greater understanding of the primary neurochemical defect in TS would be extremely valuable for the development of new tic-suppressing
therapies. Nevertheless, recognizing the varied and complex interactions that exist in a multi-neurotransmitter system, successful therapy may not require direct
targeting of the primary abnormality.
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Introduction
Tourette syndrome (TS) is a neuropsychiatric disorder whose
primary symptoms include motor and vocal tics. Tics are defined as
quick, rapid, recurrent, non-rhythmic, brief movements or vocaliza-
tions that have a waxing and waning course. Tics are common in the
pediatric population, with estimates of their presence in about 20% of
children.1 For the diagnosis of TS, an individual must have multiple
motor and at least one vocal tic, a waxing and waning course, and a
duration of tics for greater than 1 year. Affected individuals with only
motor or vocal tics for more than a year are labeled chronic motor or
vocal tic disorders and those with a tic history of less than 1 year,
a provisional disorder. Tics are typically exacerbated by stress, anxiety,
and fatigue and, especially in older children and adults, are preceded
by a premonitory sensation or urge. Therapeutically, there is no cure
for tics, and symptomatic treatment is recommended when tics are
causing psychosocial difficulties, physical discomfort, or other lifestyle
disruptions. Behavioral therapy has been effective,2 but many indivi-
duals continue to require tic-suppressing pharmacotherapy. Recog-
nizing a variability in physician selection, first-tier pharmacotherapies
often include the alpha-adrenergic agonists (clonidine, guanfacine) and
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anticonvulsants (topiramate), and second-tier the atypical (aripiprazole,
risperidone, ziprasidone, quetiaprine) and typical (pimozide, fluphe-
nazine, haloperidol) antipsychotics as well as vesicular monoamine
transporter type 2 (VMAT-2) inhibitors (tetrabenazine) Table 1. The
efficacy of current pharmacotherapeutic agents and future therapies
for tics should be understood in the context of the pathophysiologic
model underlying this movement abnormality.
The goal of this review is to integrate our current understanding of
the pathophysiology of TS with present and proposed pharmacothera-
pies for tic suppression. In the following sections, we review the
proposed anatomical pathways (cortical-basal ganglia-thalamo-cortical
[CBGTC]), and the hypothesized alterations of neurotransmitter
systems located within these circuits. Within each specific transmitter
system, we review the mechanism of action and efficacy of standard
and emerging pharmacotherapeutic agents used for tic suppression.
Our hope is that integrating the biochemical alteration(s) underlying
tics with knowledge of the mechanism of drug action will ultimately
lead to better treatment.
Overview of the CBGTC circuit
A fundamental understanding of CBGTC circuitry and its integra-
ted neurotransmitter systems are essential for understanding poten-
tial pathophysiological mechanisms and therapies in TS. As will be
described, involved circuits represent a dynamic web of interlinked
reverberating inhibitory and excitatory influences providing potential
multiple sites of influence (Figures 1 and 2). Essential individual com-
ponents include the following:
1) Cortex: Multiple regions within the cortex provide the striatum
(caudate and putamen) with excitatory glutamatergic input: e.g.,
pyramidal neurons within frontal associative/cognitive regions project
to the caudate; pre-motor/supplementary motor areas (SMAs) project
to the putamen; and emotional (limbic) regions to the ventral striatum.
These projecting cortical neurons are themselves influenced by various
neurochemical afferent inputs from interneurons (gamma-aminobutyric
acid [GABA]), the ventral tegmental area (VTA, dopamine), median
raphe (serotonin), locus coeruleus (catecholamines), and other intracor-
tical connections. In addition to the sites within the striatum, cortical
regions also send projections to the subthalamic nucleus (STN), VTA,
substantia nigra, thalamus, and via the pontine nucleus to the cerebellum.
2) Basal ganglia: Within the striatum, GABAergic medium-sized
spiny neurons (MSNs), giant aspiny cholinergic interneurons, and
several subtypes of medium-sized GABAergic interneurons receive
cortical glutamatergic inputs. Striatal MSNs and interneurons also
receive glutamatergic afferent input from motor and intralaminar
thalamic nuclei; dopaminergic projections from the substantia nigra
pars compacta (SNpc) and VTA; GABA, substance P, and enkephalin
input from other MSNs; and acetylcholine, GABA, or peptidergic
input from striatal interneurons. The STN, populated mainly by
glutamatergic projection neurons, receives its major afferents from the
cerebral cortex, thalamus, globus pallidus externa (GPe), and brain-
stem. A direct input from the inferior frontal and dorsomedial frontal
cortex to the STN has a ‘‘reactive inhibition’’ role. Outputs from the
STN project not only to the globus pallidus interna (Gpi)/substantia
nigra pars reticulate (SNpr), but also to the GPe, striatum, and
peduculopontine tegmental nucleus (PPTg).3,4
3) Thalamus: The motor thalamus (Mthal, i.e., ventroanterior and
ventrolateral nuclei) is part of a closed loop, receiving input from
cortical associatives, premotor and motor areas, basal ganglia (SNpr
and GPi), and the cerebellum (dentate nucleus). It provides excitatory
(glutamatergic) innervation to dendrites of cortical pyramidal neurons
located in layers I and II and to a lesser extent in layer V.5 In addition,
short subcortical loops exist between the thalamus and the striatum:
motor information entering to the striatum from the Mthal and
sensory information from the intralaminar nuclei.6
Possible location of the primary abnormality within the
CBGTC circuit
Prior reports have typically presented pathophysiologic hypotheses
for tics based on potential abnormalities in: 1) direct and indirect
motor pathways; 2) as a favored alteration within a particular CBGTC
region/neurotransmitter; or 3) the concept of a complex circuit
in which a failure anywhere along the pathway can alter cortical
excitability and enable the tic.
1) Direct and indirect motor pathways: One commonly pre-
sented, but overly simplistic, model of motor behavior suggests inter-
play of two distinct pathways, the ‘‘direct’’ and ‘‘indirect’’ pathways7
(Figures 1 and 2). The direct pathway transmits striatal information
monosynaptically from GABAergic MSNs, containing dopamine
receptor type 1 (D1), M1/M4 muscarinic cholinergic, and histamine
receptors, to the GABAergic GPi/SNpr region – this pathway thus
inhibiting the inhibitory GPi/SNpr output. The indirect pathway, in
contrast, conveys information from MSNs, containing dopamine
receptor type 2 (D2), M1, and adenosine a2 adrenergic receptors, to
the GABAergic GPe, from the GPe to the glutamatergic STN, and
then on to the GPi/SNpr; this pathway thus stimulates the inhibitory
GPi/SNpr output. In turn, both pathways have a reverse effect on
spontaneously firing thalamocortical neurons and ultimate motor
activity, i.e., activation of the direct pathway facilitates motor activity
via disinhibition of thalamocortical neurons whereas activation of the
indirect pathway reduces motor activity by increasing the inhibition of
thalamocortical neurons. While studies in some non-human primates
suggest that concurrent activation of projection neurons in direct and
indirect pathways produce contraversive movements,8 they fail to
recognize the complex nature of other interactions within the basal
ganglia including communications between D1 and D2 receptor
striatal MSNs; MSNs with collaterals in both the GPi and GPe; GPe
projections going back to the striatum; GPi/SNpr projections, not only
to the thalamus, but to the PPTg, habenula, and the superior
colliculus, as well as a checks and balance functionally dynamic system
regulated by mesolimbic and dopaminergic neuronal circuits.9–12
2) Alteration within a particular CBGTC region: An additional
pending question in TS is which region within the CBGTC circuit
represents the primary originating physiologic abnormality? As will be
briefly described, there is potential supporting data for several areas.
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a) Cortex: Evidence supporting a primary cortical involvement in
tics includes 1) the frequent association of tics with neuropsychiatric
comorbidities, e.g., executive dysfunction,13,14 cognitive inhibitory
deficits,15 attention deficit hyperactivity disorder (ADHD), obses-
sive–compulsive disorder (OCD), anxiety, mood disorder, and
disruptive behaviors;16 2) the presence of a preceding sensory
premonitory urge that is associated with activation in mesial and
lateral premotor areas, the insula, SMAs, anterior cingulate cortex,
and primary sensorimotor cortex;17 3) post-mortem studies
demonstrating a greater number of changes in prefrontal regions
(Brodmann area 9) than in caudate, putamen, or ventral
striatum;18,19 4) volumetric magnetic resonance imaging (MRI)
studies reporting larger dorsal prefrontal and parietal-occipital
areas,20 changes in prefrontal, frontal, sensorimotor, cingulate, and
temporal areas,21 and alterations of the corpus callosum; 5) fun-
ctional connectivity studies showing increased connections between
cortical-basal ganglia networks or widespread immature functional
connectivity; 6) demonstrated areas of cortical hypermetabolism in
positron emission tomography (PET) studies; 7) reduced inhibition
within the motor cortex as demonstrated by transcranial magnetic
stimulation (TMS); and 8) various animal models showing that
disruption of cortical function leads to tic-like behaviors.
b) Basal ganglia: Evidence supporting a basal ganglia involvement
includes 1) it’s association with other movement disorders;
2) postmortem studies showing reduced density of parvalbumin
positive interneurons, choline acetyltransferase positive choliner-
gic interneurons, and MSNs in the striatum;22,23 3) inconsistent
imaging studies of the caudate and putamen;24–26 4) studies in
human primates, rats, and mice, demonstrating that the disrup-
tion of the glutamate/GABA balance within the striatum causes
tic-like behaviors.27–30
c) Other potential regions: Although many investigators focus on
alterations within cortical and basal ganglia regions, there is
preliminary imaging and animal model support for the involve-
ment of the amygdala, hippocampus, ventral striatum, thalamus,
and cerebellum. The ventral striatum, composed of the nucleus
accumbens (NAc) and olfactory tubercle, serves as an integrating
site for emotion, motivation, vigor, and attention, via inputs from
the prefrontal cortex, anterior cingulate gyrus, hippocampus, and
amygdala. Ultimately, these inputs culminate in the dorsal stria-
tum where they influence motor output through alterations in the
levels of glutamate, GABA, histamine, and dopamine.5,31 The
Mthal is a major node linking cortical-striatal-basal ganglia and
cortical-cerebellar networks. In three subjects receiving deep
brain stimulation therapy, electrophysiological recordings showed
that spontaneous motor tics are preceded by repetitive coherent
thalamo-cortical discharges.32 Lastly, the cerebellum has been impli-
cated as a site of abnormality based on animal models demon-
strating that neurons in the cerebellar cortex and dentate nucleus
have both increased abnormal discharges and blood flow
immediately preceding tics.33 The latter has been used to counter
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is also supported by computational model analyses that repro-
duce anatomical and functional features of the Cortical-basal
ganglia-thalamo-cortical and basal ganglia-cerebellar-thalamo-
cortical networks.34
CBGTC neurotransmitters: their pathophysiologic role and
pharmacotherapy
At the biochemical level, proper conveyance of messages through
CBGTC circuits and the maintenance of stable connections require
functionally integrated neurotransmitter systems. In the following
sections, we discuss the role of specific neurotransmitters within the
CBGTC; evidence implicating a specific transmitter’s pathogenic
role in causing tics; and the selection and utilization of pharmaco-
logic agents that address the proposed abnormality. Specific neuro-
transmitters to be reviewed include dopamine, glutamate, GABA,
norepinephrine, serotonin, histamine, acetylcholine, endogenous
opioids, and cannabinoids. In general, evidence associating a parti-
cular neurotransmitter with tics includes clinical responses to specific
classes of medications; genetic protocols; measurements in blood,
urine, and cerebrospinal fluid (CSF); imaging protocols (PET, single-
photon emission computed tomography [SPECT], and magnetic
Figure 1. Cortical-Basal Ganglia-Thalamo-Cortical Circuit and their Interconnected Pathways. Abbreviations: CM-PF, Centromedial-parafascicular
Nucleus; GPe, Globus Pallidus Externa; GPi, Globus Pallidus Interna; Hypo, Hypothalamus; Mthal, Motor Thalamus; NAc, Nucleus Accumbences; SMA,
Supplemental Motor Area; SNT, Subthalamic Nucleus; SNpc, Sustantia nigra paras compacta; SNpr, Sustantia nigra paras reticulate; PN, Pontine Nucleus; PPTg,
Peduculopontine Tegmental Nucleus; VTA, Ventral Tegmental Area.
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Figure 2. Neurotransmitters within Cortical-Basal Ganglia-Thalamo-Cortical and Interconnecting Pathways. Abbreviations: ACh, Acetylcholine;
CM-PF, Centromedial-parafascicular nucleus; Glu, Glutamate; GABA, Gamma (c)-aminobutyric acid; GPe, Globus Pallidus Externa; GPi, Globus Pallidus Interna;
Hypo, Hypothalamus; Mthal, Motor Thalamus; NAc, Nucleus Accumbences; SMA, Supplemental Motor Area; SNT, Subthalamic Nucleus; SNpc, Sustantia nigra
paras compacta; SNpr, Sustantia nigra paras reticulate; PN, Pontine Nucleus; PPTg, Peduculopontine Tegmental Nucleus; VTA, Ventral Tegmental Area.
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resonance spectroscopy [MRS]); neurochemical assays on postmor-
tem brain tissues; and/or animal studies. Although each neuro-
transmitter is discussed independently, it is essential to recognize that
there are significant interactions among the multiple neurotransmit-
ters and an alteration in one system could effectively modify a second
or third agent (Figure 2). For example, in the striatum, both D1 and
D2 MSNs receive input from cortex and thalamus (glutamate), local
GABAergic and cholinergic interneurons, reciprocal connections
with neighboring MSNs (GABA, encephalin, substance P), neuro-
modulators (dopamine, serotonin, noradrenaline), and from histami-
nergic neurons located in the hypothalamus. It is also important
to recognize that studies in patients can be influenced by age at
evaluation, gender, presence of existing comorbidities, current and
prior medication use, and nuances of the selected methodology.
Dopamine
Dopaminergic pathways include three primary systems: nigrostriatal
(from SNpc to dorsal striatum and basal ganglia); mesocortical (from
VTA and some dorsal caudal extensions within the dorsal raphe
nucleus (DRN) and ventrolateral periaqueductal grey regions to the
frontal cortex), and mesolimbic (from VTA and some dorsal caudal
extensions to the ventral striatum). Although not designated a specific
system, both the SNpc and VTA provide dopaminergic input to the
thalamus. Immunohistochemical studies have also identified a nigro/
mesothalamic dopaminergic system in human and macaque monkeys
with greatest dopamine innervation to the ventral lateral and ventral
anterior motor nuclei.35,36 Further, depending on the dopamine
receptor subtype, a post-synaptic dopaminergic effect can be either
excitatory (D1) or inhibitory (D2).6,35,37,38 Dopamine has a long-
standing established role in motor activity, various movement
disorders, temporal processing, regulating reward and reinforced
learning, sensorimotor integration, cognitive function, and aver-
sion.39–42 Evidence supporting a dopaminergic abnormality in TS is
extensive and includes the recognition that the most effective tic-
suppressing medications are dopamine receptor antagonists. Further,
recognizing that tics have been labeled as a habitual behavioral
disorder,43,44 studies in animal models have shown that increasing
dopaminergic activity enhances the progression from goal-directed
to habitual behaviors. Nevertheless, despite a strong sense that
dopamine is involved in tic pathophysiology, due in part to
inconsistent studies, hypothesized abnormalities have ranged from
1) an increased number of postsynaptic dopamine receptors or a
greater dopamine receptor affinity; 2) increased dopamine innerva-
tion; 3) a presynaptic dopamine abnormality; and 4) an increased
release of dopamine.
CSF studies in TS patients performed four decades ago identified
reduced baseline levels of the dopamine metabolite homovanillic acid
(HVA) and its elevation following treatment with haloperidol.45 Uncon-
jugated plasma HVA levels, however, did not correlate with tic severity
scores46 and concentrations of dopamine, HVA, and 3, 4-dihydrox-
yphenylacetic acid were not elevated in post-mortem striatal samples.47
Protocols quantifying dopamine receptor binding in different brain
regions have included both post-mortem tissue assessments and in vivo
(PET or SPECT) methodologies. Unfortunately, results have been
inconsistent. Labeled binding to the dopamine transporter or to the
VMAT-2 have been utilized to identify excess dopamine innervation.
Again, studies have produced variable results. In a single report, an
excess accumulation of [18F]-fluorodopa led to suggestions of upregula-
tion of dopa decarboxylase activity;48 however, a subsequent study
found no differences.49
Proposed abnormalities of dopamine release have included both
tonic (low basal) and phasic (burst firing) dopamine release systems.50
Confirmation of an alteration of tonic release would be expected to be
associated with a change in baseline D2 receptor binding, e.g., increase
tonic release would lead to a down regulation of post-synaptic dopa-
mine receptors. However, as noted previously, there is great variability
in receptor binding data. Several studies have quantified phasic
dopamine release by assessing differences between sequential ([11C]-
raclopride or [11C]-FLB457) PET scans, the first following an intra-
venous injection of saline and the second after an intravenous injection
of amphetamine. Using this methodology, increased phasic release
was documented in the putamen, medial frontal gyri, and anterior
cingulate cortex.51 PET studies in TS patients, following symptom
improvement using deep brain stimulation, have suggested that clinical
improvement is associated with a decrease in dopamine release and an
upregulation of dopamine receptors.52 A conflicting dopamine release
study has been published in TS patients without OCD;53 however,
differences are possibly explained by variations in PET acquisition and
amphetamine administration. Clinical data supporting an increased
phasic burst hypothesis also include the exacerbation of tics by stress
and anxiety, a suggested exacerbation by stimulant medications, and
tic suppression with very low doses of dopamine agonists. In summary,
DA is a crucial factor in the dynamic modulation of the motor output
of the CBGTC circuit and further studies are required to clarify its
precise role in TS.
1) Dopamine-modulating pharmacotherapy in TS: Dopamine
modulating pharmacotherapies for tic suppression, although effective,
are generally not the initial prescribed medication, due to their
potential side effects. Several recent reviews provide in-depth updates
on the efficacy and safety of this therapy.54,55 Recognizing the varied
pathophysiologic hypotheses discussed above, it is not surprising that
approaches to therapy have included the use of dopamine antagonists,
VMAT-2 inhibitors, and dopamine agonists.
a) Dopamine antagonists: Medications in this category fall broadly into
two categories: typical and atypical antipsychotics.
i) Typical antipsychotics, i.e., primary dopamine antagonists, can be
subdivided based on their effect on a particular dopamine
receptor. The two US Food and Drug Administration (FDA)-
approved drugs in this category pimozide (a diphenylbutylpi-
peridine derivative) and haloperidol (a butyrophenone deriva-
tive) are both D2 antagonists with potential influences on
the indirect pathway, plus numerous other dopamine sites.
Pimozide is generally preferred, because of fewer side effects.
Sulpiride and tiapride, substituted benzamides, have been
Tics: Pathophysiology and Pharmacotherapy Augustine F, Singer HS
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beneficial in European trials, but are not available in the
United States. A new D1 receptor antagonist, ecopipam, via a
possible effect on the direct pathway (or other), has been
shown to be beneficial in adults56 and children57 with TS.
Fluphenazine, a phenothiazine derivative and combined D1
and D2 receptor inhibitor, has also been shown to be effective
in several small studies and a retrospective chart review.
Metoclopramide, which differs from other typical dopamine
antagonists because of its lack of neuroleptic-like effects in the
prefrontal, entorhinal, and ventral striatal cortices, was
effective and well tolerated in a small controlled study.58
ii) Atypical antipsychotics (aripiprazole, risperidone, olanzapine,
ziprasidone, quetiaprine, paliperidone) are characterized by a
relatively greater affinity for 5-HT2 receptors than for D2
receptors, fewer extrapyramidal side-effects, and a potential
benefit for behavioral comorbidities (anxiety, mood, disruptive
behaviors). Aripiprazole, approved by the FDA for the treat-
ment of tics, differs from other atypical neuroleptics by acting
as a partial agonist at D2 post- and presynaptic receptors, the
latter decreasing dopamine release. It also binds to 5-HT,
histamine, and a-adrenergic receptors. Risperidone, a 5-HT2
receptor antagonist at low doses and D2 antagonist at higher
doses, has moderate affinity for a-2 and histamine-1 receptors,
and is effective in reducing tics. Long-term side effects seen
in patients receiving either typical or atypical antipsychotics
include weight gain, sedation, drowsiness, hyperprolactine-
mia, extrapyramidal symptoms, tardive dyskinesia, and
QTC prolongation. It has been suggested that tardive
dyskinesia is an uncommon side effect in TS patients treated
with antipsychotics.59
b) VMAT-2 inhibitors exert their effect by blocking the transport
of dopamine into presynaptic vesicles and depletion of the level of
dopamine at the synaptic terminal. Tetrabenazine, a benzoquino-
lizine derivative, has been shown to be beneficial in open label
trials.54 Concerns, however, exist regarding its use in individuals
with depression and suicidality. Two new VMAT-2 inhibitors,
approved for use in tardive dyskinesia, are currently being evalua-
ted for the treatment of tics. Deutetrabenazine, a deuterated form
of tetrabenazine, provides several pharmacokinetic advantages to
tetrabenazine including a longer half-life and improved absorption.
Valbenazine, a purified parent drug of the (+)-a-isomer of tetra-
benazine has a half-life of about 24 hours. Preliminary studies
suggest that both valbenazine and deutetrabenazine have fewer side
effects than tetrabenazine, but which will be more effective for tic-
suppression remains undetermined.
c) Dopamine agonists: Dopamine agonists (pergolide, ropinirole, prami-
pexole) have been considered as potentially therapeutic approaches
for treating tics, based on their ability to presynaptically inhibit the
release of dopamine. A multicenter randomized placebo-controlled
trial with pramipexole was ineffective in suppressing tics in adole-
scents and children.60 In general, there have been relatively few studies
and pergolide has been withdrawn from the US market because of
serious potential side effects.
Glutamate
Glutamate, the brain’s primary excitatory neurotransmitter, has
essential roles in CBGTC circuits. It is the neurotransmitter of pro-
jecting neurons in the cortex (to the striatum, thalamus, cerebellum,
STN, VTA, SNpc, DRN); thalamus (to cortex, striatum); STN (to
GPe, GPi, striatum, PPTg); PPTg (to basal ganglia); and cerebellar
nuclei (to thalamus, red nucleus, vestibular nuclei).
Evidence supporting a role for glutamate in TS is derived from 1) a
small postmortem investigation showing reduced levels of glutamate in
the GPi, GPe, and SNpr.61 2) MRS: using field strength of 3T, limited
by an incomplete resolution of glutamate and glutamine, children had
no change within the dorsal striatum or anterior cingulate62 whereas in
adults Glx (glutamate and glutamine) was reduced in the striatum and
thalamus.63 Using high field spectroscopy at 7T, 5–12 year olds with
TS had elevated glutamate in the premotor cortex, but not striatum.64
The interpretation of MRS measurements of both glutamate and
GABA is restricted; values represent the gross concentration of the
substance in the entire voxel (includes neurons, glial, synaptic and
extrasynaptic spaces, and cytoplasmic and organellar zones) and dif-
ferences may be related to voxel placement or editing/fitting methods.65
3) Animal models: in rodents, disrupting the balance between glutamate
and GABA within cortical-striatal pathways induced tic-like activity and
damaging N-methyl-D-aspartate (NMDA) receptors, located on dopa-
minergic nigrostriatal neurons prevented habitual, but not goal-directed
learning.66,67 Lastly, accumulating evidence from studies employing
optogenetic and chemogenetic methodologies support a role for
glutamatergic output neurons and their targets in tic behaviors.68
1) Glutamate modulating pharmacotherapy: Glutamate-altering med-
ications have been reported to have a beneficial therapeutic effect on
obsessive–compulsive symptoms.69 In a small TS study, neither a glu-
tamate agonist (d-serine) nor a glutamate antagonist (riluzole) significantly
improved tics compared with a placebo control group.70
N-Acetylcysteine (NAC) is an amino acid supplement, which
following its conversion to cystine, causes the release of glutamate
from glial cells and, in turn, a reduced glutamate release from
neurons. In a single 12-week add-on trial comparing the addition of
NAC to placebo, no significant benefit was observed.71 Clonidine,
although defined as an alpha-adrenergic agonist and discussed
under ‘‘norepinephrine,’’ also influences the release of glutamate
and regulates spontaneous and glutamate-modulated firing activity
in medial frontal cortical pyramidal neurons.72–74
GABA
GABA, the primary inhibitory neurotransmitter, is utilized by
striatal synaptic projection neurons, striatal and cortical interneur-
ons, the GPi, and GPe. GABAergic neurons located within the VTA
modulate learning behaviors through control of dopamine and
cholinergic systems.75
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An alteration of GABAergic function in TS is supported by
postmortem, MRS, PET, TMS, and animal studies. 1) Postmortem
anatomical studies of the striatum show a reduction in the number of
GABAergic parvalbumin-containing interneurons. 2) Cortical MRS
results are variable with differences between data obtained at 3T
and 7T. For example, there are reported reductions in the primary
sensorimotor (SM1) cortex and anterior cingulate cortex; normal levels
in premotor, ventral medial prefrontal, and dorsolateral prefrontal
cortex, SM1 and primary visual cortex; and elevated values in the
SMA.69 Within the striatum, a single MRS study, using 7T, reported
no changes.64 3) PET: a single PET imaging of GABAA receptors
using [11C]-flumazenil showed decreased binding bilaterally in the
ventral striatum, globus pallidus, thalamus, amygdala and right insula.76
4) TMS: a deficiency of cortical inhibitory interneurons is suggested by a
reduction of short-interval intracortical inhibition.77 5) Animal models:
studies in human primates, rats, and mice have demonstrated that the
local disruption of striatal GABA, via the injection of bicuculine or
picrotoxin, can cause tic-like behaviors.27–30,78 This abnormal behavior
can, however, be reduced or abolished by re-correction of the cortico-
striatal GABA/Glutamate balance.
1) GABA-modulating pharmacotherapy: Baclofen, a GABAB recep-
tor agonist, has been variably effective as a treatment for TS. In an
open-labeled trial, with doses ranging from 10 to 80 mg/day for
4 weeks, significant decreases were noted in motor and vocal tics.79
In a double-blind, placebo-controlled crossover study, baclofen in
doses of 20 mg three times a day, statistically improved overall well-
being, but did not reduce motor or vocal tic activity. Clonazepam, a
benzodiazepine, is widely used for tics, despite limited studies
confirming its tic-suppressing effect. In two single-blind comparison
studies, one showed clonazepam was superior to clonidine for tic
suppression,80 and the second that clonazepam was better than
haloperidol, but only in patients with a high red blood cell to plasma
choline ratio.81 As with all benzodiazepines, its use is limited by tole-
rance and adverse reactions including sedation, short-term memory
problems, ataxia, and paradoxical disinhibition.82 Topiramate is a
broad-spectrum anticonvulsant medication that enhances the activity
of GABA and antagonizes the glutamate a-amino-3-hydroxyl-5-
methylisoxazole-4-proprionic acid but not the NMDA receptor. In a
single randomized study, topiramate was superior in reducing tics when
compared with placebo.83,84 Levetiracetam is another antiepileptic drug
with atypical GABAergic effects; enhances chloride ion influx at the
GABAA–receptor complex by reducing the effect of zinc and beta
carbolines, which interrupt the chloride flux.85 In contrast to other
GABAergic medications, levetiracetam was not beneficial for tics as
measured in both a crossover trial comparing the drug to placebo86 and
in a randomized, double-blind, crossover study with clonidine.87
Norepinephrine
Noradrenergic fibers project widely to the cerebral cortex from the
locus coeruleus and modulate frontal subcortical circuits implicated in
TS. For example, the stimulation of central a2-adrenergic receptors
causes decreased release of catecholamines through a GABA modu-
lated feedback.88
Strong evidence for a norepinephrine mechanism in TS is lacking.
Assays of norepinephrine or its metabolite 3-methoxy-4-hydroxyphe-
nylethylene glycol have been normal in post-mortem cerebral cortex
and basal ganglia as well as in plasma.47,89 Evaluations of norepi-
nephrine in CSF have been variable, ranging from increased to normal
values. The excretion of urinary norepinephrine in response to stress
(i.e., lumbar puncture) was increased in TS subjects.90 Lastly, quan-
titation of alpha-2 adrenoceptors in TS platelets were normal, but
variable in post-mortem cortex.19,89
1) Noradrenergic modulating pharmacotherapy: Therapeutically,
two alpha-adrenergic agonists (clonidine and guanfacine) have tic-
suppressing beneficial effects.91 Both have been shown to be more
effective than placebo in reducing tic severity and to have a beneficial
effect on ADHD symptomatology. A study comparing extended-
release guanfacine to placebo did not, however, confirm a clinically
meaningful effect size within the guanfacine group.92 Nevertheless,
guanfacine is known to inhibit excitatory glutamatergic transmis-
sion of the pyramidal cells in the prefrontal cortex.93 Common side-
effects include sedation, fatigue, drowsiness, orthostatic hypotension,
dry mouth, and irritability.
Serotonin
Serotonergic afferents arise from the DRN and median raphe
nucleus (MRN) in the midbrain. The DRN projects to the prefrontal
cortex and MRN to the striatum, SNpc, VTA, and NAc. dorsal raphe
nucleus (DRN) 5HT neurons receive monosynaptic input from
multiple brain regions including the prefrontal cortex (glutamatergic)
and the lateral habenula (GABAergic).94,95 The brain serotonergic
system is involved in reward processing and has been targeted in the
treatment of depression, anxiety, and schizophrenia. It has been
suggested that 5HT mediates some of its action by antagonizing the
effect of dopamine96 and that dopamine denervation can lead to
increased overall 5HT in the basal ganglia.97
Evidence suggesting a role for serotonin in TS is derived from
serum, CSF, PET, and animal studies. Serotonin and its precursor
tryptophan have been reported to be reduced in serum98 and 5-HIAA
(a serotonin metabolite) to be decreased in CSF99 and basal ganglia,100
but normal in the cortex.89 [123I]-b2-beta-carbomethoxy-3-beta
(4-iodophenyl) tropane (CIT) binding to the serotonin transporter
has been variable; one report identified a negative correlation between
binding in the midbrain and vocal tic severity;101 and in a second, a
trend towards a negative correlation between binding ratios and the
severity of associated Obsessive Compulsive Behavior (OCB).102 [18F]-
Altanserin PET showed increased 5-HT2A receptor binding in
multiple brain regions, including those not believed to be involved in
the disorder.103 PET of tryptophan metabolism has demonstrated
decreased uptake in the dorsolateral prefrontal cortical regions and
increased uptake in the caudate nucleus and thalamus.104 In a mouse
model, the injection of a 5-HT2A, 5-HT2B, and 5-HT2C receptor
agonist (2,5-dimethoxy-4-iodoamphetamine produced a repetitive
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head twitch.105 This movement was altered by treatment with a variety
of neurotransmitter (glutamate, GABA, dopamine, cannabinoids,
acetylcholine, norepinephrine, and adenosine) altering agents, suggest-
ing wide ranging and complex interactions.
1) Serotonin modulating pharmacotherapy: Other than studies with
atypical antipsychotics, which have 5-HT2A receptor antagonism, there
have been minimal reports. In general, selective serotonin reuptake
inhibitors do not suppress tic activity.
Histamine
Histamine is a monoamine neurotransmitter synthesized from
histidine by the enzyme L-histidine decarboxylase (HDC).106,107 Hista-
minergic neurons are in the tuberomammillary nucleus of the posterior
hypothalamus and send projections throughout the CNS, including the
forebrain and striatum. Histamine 3 (H3) receptors are found in high
concentration in the cortex, striatum, amygdala, substantia nigra, and
hippocampus, as well as on both histamine nerve terminals and post-
synaptic cells.106,108 Furthermore, it has been demonstrated that D1
receptors on striatal MSNs in the direct pathway form heterodimers
with H3 receptors (D1–H3) to exert complex inhibitory influences on
the neurons within the direct pathway.109 In general, the histamine
system is involved with the pre and post synaptic regulation of neuro-
transmitter release for dopamine, glutamate, GABA, serotonin, acetyl-
choline, and some neuropeptides.106
The link between histamine and TS was initially based on a genetic
analysis in a two-generation autosomal dominant pedigree, in which a
rare nonsense mutation (Trp317X) was identified in the HDC gene;110
an uncommon finding in the TS population.111 In animal models, a
HDC knockout mouse, with negligible histamine levels, exhibits stereo-
typic movements and spontaneous tic-like symptoms after the intra-
peritoneal injection of amphetamine.112 Similar movements were
produced in this model following H3R receptor activation in the dorsal
striatum with both r-aminomethyl-histamine and immepip. The value
of the HDC mouse as model for TS and related conditions has been
recently reviewed.113
1) Histamine modulating pharmacotherapy: Data on H3 receptor
agonists/antagonists and their usefulness in reducing tics is limited.
In a single patient with TS and cataplexy, the medication pitolisant, an
inverse agonist of the H3 receptor, did not decrease tics.114 A recent
trial with AZD5213, a histamine H3 receptor antagonist, showed a
2–3-point decrease in the Total Tic Severity Score compared to
placebo.115
Acetylcholine
Cholinergic fibers project from the basal forebrain to the cortex and
from the lateral tegmental area to the locus coeruleus. In the striatum,
large aspiny cholinergic interneurons innervate MSNs and other
interneurons. It has been suggested that these cholinergic interneurons
co-opt dopamine terminals and drive GABA release.40 Data from a
rodent model, evaluated with electrophysiological recordings com-
bined with optogenetics, suggest that nicotinic acetylcholine receptors
affect striatal neurotransmission via excitatory inputs onto MSNs.116
The strongest evidence supporting involvement of this neurotrans-
mitter in TS are post-mortem reports showing that the regional density
of choline acetyltransferase (ChAT) containing interneurons is reduced
in the caudate and putamen.23 In adult TS post-mortem frontal,
temporal and occipital brain regions, no significant differences were
identified for ChAT activity89 and receptor-binding for muscarinic
cholinergic ([3H]-quinuclidinyl benzilate, QNB) receptors showed no
generalized impairment. In contrast, using circulating lymphocytes as
a method to quantify changes in CNS muscarinic receptors, [3H]-
QNB binding was reduced in untreated TS patients.117 In CSF,
measurements of acetylcholinesterase and butyryl-cholinesterase acti-
vities did not differ from controls.118 In mice, ablation of 50% of cho-
linergic interneurons in the dorsomedial striatum caused no effect.
However, ablations in the dorsolateral striatum plus a stressful stimuli
or amphetamine challenge caused tic-like stereotypical behaviors.119
1) Acetylcholine-modulating pharmacotherapy: Results of pharma-
cological studies in TS using agents that affect cortical nicotinic and
muscarinic receptors are inconsistent. The administration of choliner-
gic precursors, including choline, lecithin, and dimethylaminoethanol
(deanol) had little effect on motor tics.117,120–122 In contrast, anti-
cholinergic agents (physostigmine) reduced the frequency of motor tics
but exacerbated vocal tics.117 In an 8-week trial using mecamylamine,
a nicotinic acetylcholine antagonist, the drug was not superior to
placebo for reducing tic severity.123
Opioids
Opioid receptor agonists (i.e., endogenous b-endorphins, enkepha-
lins, and dynorphins, as well as morphine) exert their pharmacological
effects by binding to the G-protein coupled opioid receptors mu, delta,
and kappa. Mu and kappa receptors are primarily located in basal
ganglia regions and thalamus, whereas delta receptors are predomi-
nant in the striatum, STN, and GP.124 MSNs in the indirect path-
way express enkephalin and those in the direct pathway express
dynorphin.125 Endogenous opioids are believed to exert a reciprocal
control between direct and indirect motor pathways via alteration of
the excitability of MSNs expressing D1 and D2 dopamine receptors
types. Although their exact mechanism of action remains unclear, the
opioid system dynamically modulates other neurotransmitters. For
example, endogenous opioids have been proposed to modulate the
release of dopamine by activating presynaptic receptors on GAB
Aergic interneurons in the mesolimbic-mesocortical dopaminergic
system126–129 (Figure 3).
Primary evidence of a role for opioids in TS includes postmortem
and CSF measurements of dynorphin. In a postmortem study,
dynorphin {1-17} immunoreactivity was decreased in striatal fibers
projecting to the GPe in a severely affected TS patient.130 In CSF,
dynorphin-A {1-18} was increased in TS patients and the concentra-
tions of this opiate correlated with the severity of obsessive compulsive
symptoms, but not with tic severity.131 Studies in multiple animal
models have suggested a functional communication between opioid
receptors and the dopaminergic system. Pharmacological studies, in a
wide variety of primate and non-primate species, have highlighted the
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induction of stereotyped behaviors by apomorphine and morphine.132–135
Dual acting opioid receptor agonist and antagonist combinations (i.e.,
nalbuphine, nalorphine, pentazocine, butorphanol, and related com-
pounds) have been used to selectively treat levodopa-induced dyskinesia.
For example, macaques, receiving intravenous nalbuphine, a mu receptor
antagonist and kappa receptor agonist, had resolution of their levodopa-
induced dyskinesia.124
1) Opioid-modulating pharmacotherapy: Clinical trials of naloxone,
an opioid receptor antagonist, in TS have produced conflicting results.
Some investigators found dramatic improvements in OCD,127 whereas
others identified only a rare responder. In one double-blind
randomized clinical trial of naltrexone, subjects reported reduction
of tics compared to the placebo control group.136 The unmasking of
TS-like symptoms following withdrawal from opiates has been cited as
further evidence for their possible role in TS.137 Clearly, additional
double blind, placebo-controlled studies are required to further
establish the usefulness of opioids in TS. Concerns regarding the
potential use of opioid therapy include addiction, decreased gastro-
intestinal motility, sedation, dyspnea, vomiting, euphoria, anorexia,
urinary retention, and dysphoria.138
Cannabinoids
The endocannabinoids, N-arachidonoyl ethanolamine (AEA), and
2-arachidonoyl glycerol (2-AG), are naturally occurring compounds
that bind to cannabinoid receptors (CBRs), specifically cannabinoid
receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2). CB1
receptors, based on immunoreactivity assays, are located in the pre-
frontal cortex near glutamatergic fibers and within the striatum,
cerebellum, and GP near pre- and post-synaptic GABAergic inter-
neurons.117–119 CB2 receptors, initially believed to be solely periph-
eral, have been identified in the striatum, VTA, hippocampus, and
thalamus. Both AEA and 2-AG are synthesized on demand from post-
synaptic membrane phospholipids, which diffuse and bind to the pre-
synaptic CBRs, and inhibit neurotransmitter release via retroactive
feedback inhibition.139,140
The presence of CBRs on dopaminergic axons remains controver-
sial, and the functional interaction between cannabinoids and the
dopamine system is subject of current investigations. In general, the
endocannabinoid system exerts a broad neuromodulatory effect within
the CBGTC circuitry through 2-AG and AEA retroactive feedback
inhibition and via recruiting several second messenger systems
(adenosine triphosphate [ATP], cyclic adenosine monophosphate,
nitric oxide, and hydrogen peroxide [H2O2]) that also cause a decrease
in neurotransmitter release.
Evidence for endocannabinoid involvement in TS comes from a
very limited number of SPECT studies quantifying CB1 receptor
binding using [123I]-AM281141 and the results of therapeutic trials
(discussed below). In addition, a study has linked cannabis use in the
last 2 months of pregnancy with an increased risk of TS in children.142
In mice lacking CB1 receptors, animals had difficulty learning a habit-
based protocol.139 In a 2,5-dimethoxy-4-iodoamphetamine-induced
head twitch mouse model, cyclohexyl-carbamic acid 39-carbamoyl-
biphenyl-3-yl ester (URB597), an indirect cannabinoid agonist that
enhances endogenous AEA levels, mitigated the tic-like head
movements.143
1) Cannabinoid-modulating pharmacotherapy: Several case reports
and two small placebo-controlled studies have suggested that
cannabinoids (smoking marijuana or using oral delta-9-tetrahydro-
cannabinol (THC)), has a beneficial effect on tics in TS patients.144,145
For example, a 6-week double-blind placebo controlled trial of THC
in 24 TS patients showed a significant reduction in a self-reported
severity scale.146 Additionally, in two case studies, individuals with
severe comorbidities and complex TS reported a positive response to
treatment with nabiximol, a combination of THC and CBD.147,148
Nevertheless, the use of cannabis-based pharmacotherapy remains
controversial. Medical marijuana, MarinolH (dronabinol, THC) and
EpidiolexH (CBD) are manufactured under FDA-regulated guidelines.
Production guidelines, however, may vary in other regions of the
world.149–151 MarinolH has been marketed for anorexia and as an
antiemetic, whereas EpidiolexH was recently approved by FDA as a
treatment of rare forms of epilepsy. Neither drug has received approval
as a treatment for TS. The most common side effects are sedation,
dizziness, headaches, ‘‘high’’ (euphoria feelings), red eyes, increased
appetite, psychosis, depression, and cognitive impairment.152,153 To
date, it is generally accepted that there is insufficient evidence to
recommend the use of cannabinoids in TS.
A second investigative approach to cannabinoid therapy involves
attempts to modulate the endocannabinoid system. In a recent phase
1B study, increasing the levels of 2-AG, by inhibiting its degradative
enzyme monoacylglycerol lipase (MGLL), using the selective com-
pound ABX-1431, reduced motor tics and premonitory urges.154
Although describing a new and unique approach, additional studies
containing a larger sample size, longer therapeutic period, and controls
for prior cannabinoid usage, are required.
Conclusions
As summarized, there has been an extensive effort devoted to
clarifying the underlying pathophysiology of tics. Nevertheless, to date,
the precise anatomical site of origin and primary underlying neuro-
transmitter abnormality remains undetermined. Potential explanations
for the slow advancement are varied and include the complex nature
of TS, with unpredictable and fluctuating motor and vocal tics that are
confounded by the presence of multiple neuropsychiatric comorbid-
ities. Discrepancies in anatomical, biochemical, imaging, and ther-
apeutic trials are often attributed to subject age, gender, variable
scales, prior or ongoing therapies, study design, methodologies,
specificity, data analysis, etc. Concerns regarding animal models
include a failure to recapitulate the human situation, the inclusion
of non-tic movements, and anatomical differences between animal
models and human subjects. Although it is important to note these
limitations, it is essential to acknowledge the ongoing scientific
advancements in our understanding of the complex and intricate
interactions within the CBGTC circuits.
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Figure 3. Diagram Showing the Interactions of Pharmacological Agents Used for Tic Suppression, and their Proposed Pre and Post-Synaptic
Effects. a2-Agonists exert their effects on the pre and post synaptic a2-receptors while allosterically enhancing the affinity of GABA for the GABA-receptor
complex (GABA-R). Post-synaptically, a2-Agonists enhance the synaptic impulses in recipient neurons by closing the hyperpolarization-activated cyclic nucleotide
gated (HCN) channels and decreasing the cation ion efflux. Pre-synaptically, a2-Agonists inhibit excitatory glutamatergic transmission of the pyramidal cells in the
prefrontal cortex. The effects of D1 and D2 receptor agonist/antagonist interactions have been recently reviewed.54 The mechanistic effects of D1-H3 and D2-H3
receptor heterodimers are inhibitory at the post-synaptic terminals. Dopamine has been shown to exert an inhibitory control over medium-sized spiny neurons
(MSNs) when acting through D1-H3 heterodimers. This is in contrast to D1 receptor functionality in the direct pathway, where dopamine has an excitatory effect on
D1 expressing MSNs. Cannabinoid receptor type 1 (CB1), on the glutamatergic and GABAergic corticostriatal projections is activated by 2-AG and AEA binding.
These endocannabinoids are released by post synaptic membrane phospholipids. One intracellular effect of presynaptic CB1 activation on GABAergic interneurons
is the increased production of mitochondrial H2O2. This H2O2 diffuses to adjacent axonal release sites, where it activates H2O2-sensitive KATP channels, leading to
synaptic depression. Opioid receptors (mu, kappa, and delta) are activated by endogenous and exogenous opioid agonists. Although the exact mechanisms are
unknown, however, the endogenous opioids are proposed to decrease the GABAergic tone within mesolimbic-mesocortical system by inhibiting voltage-sensitive
Ca2+ channels, enhancing the outflow of K+ ions, and inhibiting the intracellular adenylate cyclase.
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In terms of localization, there is a general tendency to favor a site or
component of the CBGTC circuit, rather than noting its multifaceted,
interactive nature. For example, recent studies have emphasized the
potential importance of an expanding list of cortical inputs with both
excitatory and inhibitory roles; the emotional and motivational impact
of the ventral striatum; the essential integrating role for the Mthal,
interconnections with the cerebellum, and an ever-expanding number
of feedback loops.155 Hence, while we await future scientific advances
and more definitive data, our working model is that a disruption
anywhere within the CBGTC circuit, or even one involving regions
inputting to the circuit, can lead to an aberrant message arriving at the
primary motor cortex.
At the biochemical level, the identification of the definitive primary
neurochemical abnormality remains a challenge. In this report, we
describe potential evidence supporting proposed abnormalities of nine
different neurotransmitter systems. Although controversial,156,157 the
authors favor a functional involvement of the dopaminergic system,
likely an alteration of phasic release. This bias is based on involvement
in prior PET and laboratory studies and the overwhelming evidence
that dopamine-modulating agents are the most effective tic-suppressing
medications. Despite this claim, we readily note numerous studies,
especially in animal models, that identify imbalances in other neuro-
transmitter systems. Once again, it is essential to recognize that these
are complex integrated systems. For example, a change in one neuro-
transmitter has a significant effect on the functional activity of other
interconnected systems. Hence, a future important goal will be to
determine whether an identified abnormality is a primary or secondary
phenomenon, i.e., the cause of or response to having tics.
In this manuscript, we have reviewed standard and emerging
pharmacologic agents in TS based on their primary effect on a specific
neurotransmitter. Clearly, a greater understanding of the underlying
neurochemical defect in TS will lead to the development of new tic-
suppressing therapies. Nevertheless, it is important that investigators
carefully review existing data before eliminating a potential treat-
ment. For example, preliminary studies can be influenced by atypical
placebo effects, sample size, prior medication usage, etc. Finally,
when dealing with a multi transmitter, heavily inter-reactive system,
a successful therapy may not need to directly target the primary
abnormality.
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